Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Allergy & Cold Medication Recalls

Recalls of antihistamines, decongestants and nasal sprays.

314 recalls in this category, newest first.

Class II · Moderate risk

Cetirizine Oral Solution 1 mg/mL

cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL, 4oz, of the voluntary recall that they have initiated due to potential contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination P & L Developments, LLC NDC 63868-430-04 D-1408-2019
Class II · Moderate risk

Cetirizine HCL Oral Solution 1 mg/mL

cGMP Deviations: Firm was notified by their supplier of Cetirizine HCL Oral Solution, USP, 1mg/mL, 4oz, of the voluntary recall that they have initiated due to potential contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination P & L Developments, LLC NDC 55910-878-04 D-1407-2019
Class II · Moderate risk

Allergy Relief D

Testing of Fexofenadine HCl and Pseudoephedrine Failed Impurities/Degradation Specifications: elevated substance results that were reported above or near the specification limit

Terminated Impurity / degradation Sun Pharmaceutical Industries, Inc. D-1388-2019
Class II · Moderate risk

Allergy Relief D

Testing of Fexofenadine HCl and Pseudoephedrine Failed Impurities/Degradation Specifications: elevated substance results that were reported above or near the specification limit

Terminated Impurity / degradation Sun Pharmaceutical Industries, Inc. D-1387-2019
Class II · Moderate risk

Nasal Decongestant Liquid

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1371-2019
Class II · Moderate risk

Diphenhist Oral Solution

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1370-2019
Class II · Moderate risk

Guaifenesin DAC Oral Solution

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1364-2019
Class II · Moderate risk

Cetirizine HCL Oral Solution

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1361-2019
Class II · Moderate risk

Pseudoephedrine Oral Solution

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1353-2019
Class II · Moderate risk

Banophen Oral Solution

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1352-2019
Class II · Moderate risk

Allergy Liquid Antihistamine

cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).

Terminated Microbial contamination Torrent Pharma Inc D-1347-2019
Class II · Moderate risk

Fexofenadine HCl Tablets

Failed Impurities/Degradation Specifications: Related compound results obtained during routine stability testing was slightly elevated above specification.

Terminated Impurity / degradation Mylan Pharmaceuticals Inc. NDC 0378-0782-93 D-0428-2019
Class II · Moderate risk

children's allergy relief

Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.

Terminated Impurity / degradation Taro Pharmaceuticals U.S.A., Inc. D-0278-2019
Class II · Moderate risk

children's allergy

Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.

Terminated Impurity / degradation Taro Pharmaceuticals U.S.A., Inc. NDC 56062-106-08 D-0277-2019
Class II · Moderate risk

Children's 24 Hour Allergy

Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.

Terminated Impurity / degradation Taro Pharmaceuticals U.S.A., Inc. NDC 41250-106-08 D-0276-2019